Iterum Therapeutics PLC reports results for the quarter ended September 30 - Earnings Summary

• Iterum Therapeutics PLC ITRM.OQ reported a quarterly adjusted loss of 30 cents​​ per share for the quarter ended September 30, identical to the same quarter last year. The mean expectation of two analysts for the quarter was for a loss of 20 cents per share. Wall Street expected results to range from -23 cents to -17 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Iterum Therapeutics PLC's reported EPS for the quarter was a loss of 30 cents​.

• The company reported a quarterly loss of $6.09 million.

• Iterum Therapeutics PLC shares had risen by 31.2% this quarter and lost 27.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Iterum Therapeutics PLC is 7.50

This summary was machine generated from LSEG data November 14 at 08:58 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)